Bristol-Myers Squibb Company (BMY)
| Market Cap | 89.15B |
| Revenue (ttm) | 47.70B |
| Net Income (ttm) | 5.05B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.49 |
| PE Ratio | 17.62 |
| Forward PE | 6.93 |
| Dividend | $2.48 (5.66%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 16,803,873 |
| Open | 43.43 |
| Previous Close | 43.54 |
| Day's Range | 43.27 - 43.90 |
| 52-Week Range | 42.96 - 63.33 |
| Beta | 0.34 |
| Analysts | Hold |
| Price Target | 57.54 (+31.37%) |
| Earnings Date | Oct 30, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $57.54, which is an increase of 31.37% from the latest price.
News
Final Trade: WMT, AMZN, F, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics
Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA...
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types.
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
REDMOND, Wash. , Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868...
Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs
Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...
Bristol Myers Squibb: Value Emerges From Distress
Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses fr...
Bristol Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics.
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Campaign Spotlighting the Power of Support and Connection.
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield
Bristol-Myers Squibb offers a compelling value at current lows, trading at under 7x earnings and yielding an attractive 6% dividend. BMY's resilient business model, strong cash flow, and growth from n...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Final Trade: GDX, PFE, GFS, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Alzheimers--BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease.
Bristol Myers, Takeda to pool data for AI-based drug discovery
Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and develop...
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-pr...
Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs
Seven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors. Analyst forecasts project 17.61% to...
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Bristol Myers to sell psoriasis drug at over 80% discount
Bristol Myers Squibb said on Thursday it will sell its psoriasis drug Sotyktu directly to cash-paying patients at a more than 80% discount to the drug's list price.
Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®.
Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Bristol-Myers Squibb Company (NYSE:BMY) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - Presiden...
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies.
Buy Bristol Myers Squibb Stock At $45?
Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in...
Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US
Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.